Page last updated: 2024-08-22

platinum and buparlisib

platinum has been researched along with buparlisib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S	1

Trials

1 trial(s) available for platinum and buparlisib

Article	Year
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate	2017

Article

Year

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

The Lancet. Oncology, 2017, Volume: 18, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate

2017